135 related articles for article (PubMed ID: 38346565)
1. iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors.
Wang X; Zhao Y; Yan M; Liang X; Zhao N; Lu T
Eur J Pharm Sci; 2024 Apr; 195():106725. PubMed ID: 38346565
[TBL] [Abstract][Full Text] [Related]
2. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
3. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
6. Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system.
Akbarzadeh M; Babaei M; Abnous K; Taghdisi SM; Peivandi MT; Ramezani M; Alibolandi M
Int J Pharm; 2019 Oct; 570():118645. PubMed ID: 31465835
[TBL] [Abstract][Full Text] [Related]
7. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
[TBL] [Abstract][Full Text] [Related]
8. Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles.
Huang J; Lai W; Wang Q; Tang Q; Hu C; Zhou M; Wang F; Xie D; Zhang Q; Liu W; Zhang Z; Zhang R
Int J Nanomedicine; 2021; 16():7497-7515. PubMed ID: 34803378
[TBL] [Abstract][Full Text] [Related]
9. Decapeptide functionalized targeted mesoporous silica nanoparticles with doxorubicin exhibit enhanced apoptotic effect in breast and prostate cancer cells.
Tambe P; Kumar P; Paknikar KM; Gajbhiye V
Int J Nanomedicine; 2018; 13():7669-7680. PubMed ID: 30538451
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of iRGD with Multistage Responsive Nanoparticles Enhanced Tumor Targeting and Penetration Abilities for Breast Cancer Therapy.
Hu C; Yang X; Liu R; Ruan S; Zhou Y; Xiao W; Yu W; Yang C; Gao H
ACS Appl Mater Interfaces; 2018 Jul; 10(26):22571-22579. PubMed ID: 29878758
[TBL] [Abstract][Full Text] [Related]
11. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
12. Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles.
Ávila-Ortega A; Carrillo-Cocom LM; Olán-Noverola CE; Nic-Can GI; Vilchis-Nestor AR; Talavera-Pech WA
Curr Drug Deliv; 2020; 17(9):799-805. PubMed ID: 32723272
[TBL] [Abstract][Full Text] [Related]
13. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
14. Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells.
Pullan J; Dailey K; Bhallamudi S; Feng L; Alhalhooly L; Froberg J; Osborn J; Sarkar K; Molden T; Sathish V; Choi Y; Brooks A; Mallik S
ACS Appl Bio Mater; 2022 May; 5(5):2163-2175. PubMed ID: 35417133
[TBL] [Abstract][Full Text] [Related]
15. Preparation and in-vitro evaluation of mesoporous biogenic silica nanoparticles obtained from rice and wheat husk as a biocompatible carrier for anti-cancer drug delivery.
Porrang S; Rahemi N; Davaran S; Mahdavi M; Hassanzadeh B
Eur J Pharm Sci; 2021 Aug; 163():105866. PubMed ID: 33957220
[TBL] [Abstract][Full Text] [Related]
16. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity.
Li J; Du X; Zheng N; Xu L; Xu J; Li S
Colloids Surf B Biointerfaces; 2016 May; 141():374-381. PubMed ID: 26878288
[TBL] [Abstract][Full Text] [Related]
17. Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles.
Wang Z; Li X; Wang D; Zou Y; Qu X; He C; Deng Y; Jin Y; Zhou Y; Zhou Y; Liu Y
Acta Biomater; 2017 Oct; 62():144-156. PubMed ID: 28842335
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
19. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy.
Bhavsar DB; Patel V; Sawant KK
Eur J Pharm Sci; 2020 Sep; 152():105428. PubMed ID: 32553643
[TBL] [Abstract][Full Text] [Related]
20. Poly(2-ethyl-2-oxazoline)-doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy.
Li J; Zhou Y; Li C; Wang D; Gao Y; Zhang C; Zhao L; Li Y; Liu Y; Li X
Bioconjug Chem; 2015 Jan; 26(1):110-9. PubMed ID: 25506713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
